Evidence map›Paper›PMID 39938525›Full record

ArticleCell reports. Medicine2025

Basal T cell activation predicts yellow fever vaccine response independently of cytomegalovirus infection and sex-related immune variations.

Antonio Santos-Peral, Magdalena Zaucha, Elena Nikolova, Ekin Yaman, Barbara Puzek, Elena Winheim, Sebastian Goresch, Magdalena K Scheck, Lisa Lehmann, Frank Dahlstroem and 13 more

Abstract read
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Antonio Santos-PeralDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Magdalena ZauchaDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Elena NikolovaDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Ekin YamanDepartment of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital Munich, Munich, Germany; Institute of Translational Genomics, Department of Computational Health, Helmholtz Munich, Munich, Germany.
Barbara PuzekDepartment of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital Munich, Munich, Germany; Institute of Translational Genomics, Department of Computational Health, Helmholtz Munich, Munich, Germany.
Elena WinheimInstitute for Immunology, Biomedical Center, Faculty of Medicine, LMU Munich, Munich, Germany.
Sebastian GoreschDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Magdalena K ScheckDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Lisa LehmannDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Frank DahlstroemDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Hadi KarimzadehDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Julia Thorn-SesholdDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany; Faculty of Chemistry and Pharmacy, LMU Munich, Munich, Germany.
Shenzhi JiaDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.
Fabian LuppaDivision of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Michael PritschDivision of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
Julia ButtDivision of Infections and Cancer Epidemiology at the German Cancer Research Center (DKFZ), Heidelberg, Germany.
Camila Metz-ZumaranDivision of Infections and Cancer Epidemiology at the German Cancer Research Center (DKFZ), Heidelberg, Germany.
Giovanna Barba-SpaethInstitut Pasteur, Université de Paris, CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.
Stefan EndresDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP) Helmholtz Zentrum München German Research Center for Environmental Health (HMGU), Neuherberg, Germany.
Sarah Kim-HellmuthDepartment of Pediatrics, Dr. von Hauner Children's Hospital, LMU University Hospital Munich, Munich, Germany; Institute of Translational Genomics, Department of Computational Health, Helmholtz Munich, Munich, Germany.
Tim WaterboerDivision of Infections and Cancer Epidemiology at the German Cancer Research Center (DKFZ), Heidelberg, Germany.
Anne B KrugInstitute for Immunology, Biomedical Center, Faculty of Medicine, LMU Munich, Munich, Germany.
Simon RothenfusserDivision of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP) Helmholtz Zentrum München German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address: simon.rothenfusser@med.uni-muenchen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The live-attenuated yellow fever 17D (YF17D) vaccine is a model of acute viral infection that induces long-lasting protective immunity. Among immunocompetent adults, responses to YF17D vary significantly. To understand the sources of this variability, we investigate the influence of sex, age, human leukocyte antigen (HLA) type, and 20 prior infections on basal immune parameters and the cellular and antibody response to YF17D in 250 healthy young individuals. Multivariate regression found that sex and cytomegalovirus (CMV) infection significantly contribute to baseline immune variation but do not affect vaccine responses except for reduced YF17D-specific CD8

Indexed as

Cytomegalovirus InfectionsLymphocyte ActivationT-LymphocytesYellow FeverYellow Fever VaccineAdolescentAdultAntibodies, ViralCD8-Positive T-LymphocytesCytomegalovirusFemaleHumansMaleSex FactorsVaccinationYellow fever virusAntibodies, ViralYellow Fever Vaccineadaptive immunityflavivirushuman immune variabilityimmunogenicitylive vaccinevaccine responseyellow fever vaccineYF17D

Identifiers

PMID39938525
PMCPMC11866508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.